Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q15233
UPID:
NONO_HUMAN
Alternative names:
54 kDa nuclear RNA- and DNA-binding protein; 55 kDa nuclear protein; DNA-binding p52/p100 complex, 52 kDa subunit
Alternative UPACC:
Q15233; B7Z4C2; D3DVV4; F5GYZ3; O00201; P30807; Q12786; Q9BQC5
Background:
Non-POU domain-containing octamer-binding protein (NONO) is a multifunctional protein involved in various nuclear processes, including pre-mRNA splicing, DNA repair, and transcriptional regulation. It forms complexes with other proteins, such as SFPQ, to influence DNA and RNA dynamics, playing a crucial role in cellular homeostasis and response to DNA damage.
Therapeutic significance:
NONO's involvement in Intellectual developmental disorder, X-linked, syndromic 34, underscores its potential as a therapeutic target. Understanding NONO's role could open doors to novel strategies for treating this and possibly other related genetic disorders.